News / Taiwan / cnyes
Polaris Group August Revenue Jumps 202.56% Year-on-Year
Health Technology · Biotechnology · cnyes · 2026-09-09
6550
Biotech firm Polaris Group (6550) reported a 202.56% year-on-year revenue increase for August, with year-to-date growth exceeding 108% as it advances its drug development pipeline.
What Happened
Revenue Performance: Polaris Group (6550) reported August revenue of NT$4.5 million, marking a 202.56% year-on-year increase, though monthly revenue experienced significant volatility.
Cumulative Growth: Cumulative revenue for the first eight months of 2026 reached NT$44.97 million, a 108.46% increase year-to-date, reflecting progress in its pharmaceutical development efforts.
Stock Performance: Shares are trading at NT$10.25, down 5.14% over the past five days, as investors remain cautious regarding the company's short-term revenue fluctuations.
Business Overview: Polaris Group focuses on the research, development, and manufacturing of new drugs, operating within the biotechnology sector with revenue still in the early growth phase.